688179.SHG Shanghai Aladdin Biochemical Technology Co. Ltd. A
- Market cap
- CNY 5.31B
- P/E
- 32.6x
- P/B
- 3.57x
- ROE
- 9.5%
- Dividend yield
- 1.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688179.SHG undervalued?
Graham number688179.SHG trades 127.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Aladdin Biochemical Technology Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai Aladdin Biochemical Technology Co. Ltd. A yet.
Shanghai Aladdin Biochemical Technology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Aladdin Biochemical Technology Co. Ltd. A
Shanghai Aladdin Biochemical Technology Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of scientific research reagents and laboratory consumables primarily under Aladdin and i-quip brands in China and internationally. It offers chemistry and biochemical reagents, including blocks, ligands, catalysts, chemical synthesis, laboratory chemicals, chemical biology, analytical standards, CVD and ALD precursors, and stable isotop…
Full company profileShanghai Aladdin Biochemical Technology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Aladdin Biochemical Technology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 210M | 234M | 288M | 378M | 403M | 534M | 696M | 770M |
| Gross Profit | 148M | 142M | 179M | 222M | 243M | 339M | 445M | 504M |
| Operating Income | 76.8M | 86.4M | 94.8M | 101M | 95.9M | 141M | 186M | 198M |
| EBITDA | 81.7M | 94.7M | 115M | 130M | 130M | 173M | 218M | 198M |
| Net Income | 63.7M | 74.4M | 89.4M | 92.8M | 85.8M | 98.8M | 102M | 131M |
| EPS | 0.60 | 0.27 | 0.27 | 0.28 | 0.26 | 0.36 | 0.31 | 0.36 |
| Balance Sheet | ||||||||
| Total Assets | 391M | 864M | 932M | 1.48B | 1.51B | 1.78B | 2.66B | 2.71B |
| Total Liabilities | 44.4M | 46.8M | 73.8M | 504M | 469M | 635M | 1.49B | 1.11B |
| Shareholders' Equity | 346M | 817M | 858M | 975M | 1.04B | 1.07B | 969M | 1.38B |
| Cash & Short-term Investments | 83.6M | 340M | 349M | 571M | 523M | 467M | 697M | 685M |
| Cash Flow | ||||||||
| Operating Cash Flow | 56.2M | 81.4M | 15.0M | -43.3M | 55.8M | 152M | 401M | - |
| Capital Expenditure | 6.24M | 9.10M | 113M | 62.0M | 45.7M | 35.5M | 49.0M | 5.67M |
| Free Cash Flow | 50.0M | 72.3M | -98.4M | -105M | 10.1M | 116M | 352M | -68.0M |
| Ratios | ||||||||
| ROE | 18.4% | 9.1% | 10.4% | 9.5% | 8.3% | 9.3% | 10.5% | 9.5% |
| ROA | 16.3% | 8.6% | 9.6% | 6.3% | 5.7% | 5.6% | 3.8% | 4.8% |
| Net Profit Margin | 30.4% | 31.8% | 31.1% | 24.5% | 21.3% | 18.5% | 14.7% | 17.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Aladdin Biochemical Technology Co. Ltd. A dividends
- Dividend yield
- 1.33%
- Forward dividend
- 0.14 CNY
- Payout ratio
- 69.0%
- Ex-dividend date
- Jul 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 70.5M | 0.21 | 69.0% |
| 2024 | CNY 62.9M | 0.23 | 63.7% |
| 2023 | CNY 35.4M | 0.11 | 41.2% |
| 2022 | CNY 40.4M | 0.12 | 43.5% |
| 2021 | CNY 50.6M | 0.15 | 56.6% |
| 2020 | CNY 41.9M | 0.15 | 56.3% |
| 2019 | CNY 41.8M | 0.39 | 65.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 5, 2025.
Who owns Shanghai Aladdin Biochemical Technology Co. Ltd. A
- Insiders 46.31%
- Institutions 4.84%
- Public & others 48.85%
- Shares outstanding 363M
- Free float 219M
Shanghai Aladdin Biochemical Technology Co. Ltd. A company profile
- Company name
- Shanghai Aladdin Biochemical Technology Co. Ltd. A
- Ticker
- 688179.SHG
- ISIN
- CNE100005XD0
- Exchange
- Shanghai Stock Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 926
- Fiscal year end
- December
- Address
- South Tower, Shanghai, China, 201206
- Phone
- 86 40 0620 6333
- Website
- aladdin-e.com
About Shanghai Aladdin Biochemical Technology Co. Ltd. A
Shanghai Aladdin Biochemical Technology Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of scientific research reagents and laboratory consumables primarily under Aladdin and i-quip brands in China and internationally. It offers chemistry and biochemical reagents, including blocks, ligands, catalysts, chemical synthesis, laboratory chemicals, chemical biology, analytical standards, CVD and ALD precursors, and stable isotopes; material science solutions for energy, electronic, and biomedical materials; and small molecules, such as compound libraries, ligand families, antibody-drug conjugates, and protein degradation-targeting chimeras, as well as classification by signaling pathway, target toxin, and disease. The company also provides life sciences comprising protein, antibody, and molecular, protein, and cell biology; GMP-grade products, which include bioactive small molecules, grade protein, upstream process chemicals, downstream process and formulation chemicals, and culture medium and buffer raw materials. In addition, it offers laboratory equipment, such as miscellaneous tools; tweezers, scrapers, and tools; PCR supplies and equipment; balance, scale, and weighing tools; sealing film, foil, and tape; filtration and chromatography; microscope slides; liquid handling and dispensing; sample processing; glassware; and safety, gloves, eyeglasses, and cleaning products. The company sells its reagents products under the Aladdin brand and its experimental consumables under the Core Silicon Valley brand through its e-commerce platform. Its products are used in analytical chemistry, chemical synthesis, materials science and engineering, biopharmaceutical production, drug discovery, and genomics applications. The company was founded in 2008 and is based in Shanghai, China.
Shanghai Aladdin Biochemical Technology Co. Ltd. A management
7- Mr. Jiuzhen XuChairman of the Board & GM · born 1966
- Mr. Gu WeiyuCFO, Deputy GM & Director · born 1975
- Mr. Shen HonghaoAccounting Supervisor · born 1983
- Ms. Yahong ZhaoBoard Secretary · born 1982
- Ms. Liping ZhaoDeputy General Manager · born 1980
- Mr. Hai LongDeputy Director of Technology Research & Development Department · born 1983
- Mr. Ling QingliDeputy General Manager · born 1972